169328-26-1

Basic information

• Product Name: 2-trifluoroacetylimino-5-ethyl-3-(2'-cyanobiphenyl-4-yl)methyl-1,3,4-thiadiazoline
• Synonyms: 2-trifluoroacetylimino-5-ethyl-3-(2'-cyanobiphenyl-4-yl)methyl-1,3,4-thiadiazoline
• CAS NO: 169328-26-1
• Molecular Weight: 416.427
• Mol File: 169328-26-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-trifluoroacetylimino-5-ethyl-3-(2'-cyanobiphenyl-4-yl)methyl-1,3,4-thiadiazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-trifluoroacetylimino-5-ethyl-3-(2'-cyanobiphenyl-4-yl)methyl-1,3,4-thiadiazoline(169328-26-1)
• EPA Substance Registry System: 2-trifluoroacetylimino-5-ethyl-3-(2'-cyanobiphenyl-4-yl)methyl-1,3,4-thiadiazoline(169328-26-1)

Safety Data

• Hazardous Substances Data: 169328-26-1(Hazardous Substances Data)

Upstream product

• 114772-53-1 2-Cyano-4'-methylbiphenyl 
• 22926-50-7 5-ethyl-2-trifluoroacetylamino-1,3,4-thiadiazole 
• 7440-44-0 pyrographite 
• 114772-54-2 4'-(bromomethyl)-1,1'-biphenyl-2-carbonitrile 

Downstream Products

• 169328-27-2 5-ethyl-2-imino-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl-1,3,4-thiadiazoline.hydrochloride 
• 167005-94-9 5-ethyl-2-imino-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]methyl-1,3,4-thiadiazoline 

Relevant articles and documents

Acyliminothiadiazoline derivatives: New, highly potent, and orally active angiotensin II receptor antagonists

Syntheses and pharmacological properties of a new series of acyliminothiadiazoline derivatives 1 are described. These compounds exhibited angiotensin II receptor antagonistic activities in vitro and in vivo. Among them, the compound 1g (KRH-594) showed the strongest antihypertensive action in renal hypertensive rats after oral administration, and its oral bioavailability in dogs was also found to be high (73%).

POTASSIUM SALT OF BIPHENYLMETHANE DERIVATIVE AND MEDICINE CONTAINING THE SAME

The present invention relates to mono or dipotassium 2-[[5-ethyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl-1,3,4-thiadiazolin-2-yliden]aminocarbonyl]-1-cyclopentenecarboxylate, a pharmaceutical composition containing the compound, use of the compound for pharmaceuticals, and a therapeutic method of circulatory diseases by administering the compound. The mono or dipotassium salt of the compound has a potent angiotensin II antagonist activity and anti-hypertensive effect and also has high bioavailability when administered orally so that it is useful as a pharmaceutical.